Charming Medical Limited, a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies, has received a delisting determination notice from Nasdaq. This decision, announced on November 5, 2026, follows a series of trading irregularities that led to a suspension of the company’s securities by the U.S. Securities and Exchange Commission (SEC) in 2025.

The Nasdaq notice indicates that the company’s securities will be delisted unless an appeal is filed by November 5, 2026. If the appeal is not made, trading will be suspended on November 9, 2026, and Nasdaq will subsequently file a Form 25-NSE with the SEC to remove the company’s securities from the exchange.

Background

Charming Medical Ltd operates under the ticker symbol MCTA on the Nasdaq exchange and is categorized under the SIC code 8090, which encompasses services related to miscellaneous health and allied services. The company specializes in TCM therapies and products, offering a range of services through its wellness centers in Hong Kong.

In its recent filings, Charming Medical has been transparent about its operations and financial conditions, with the most recent filing being a 6-K on November 5, 2026. The company has faced scrutiny due to trading activities that raised concerns of manipulation, prompting the SEC to suspend trading in its securities in November 2025.

What the Filing Says

The filing states, “Charming Medical Limited announces receipt of Nasdaq delisting determination notice.” It further explains that the company is evaluating its next steps with legal counsel and will make further announcements as appropriate.

Impact

This delisting could significantly affect investors and stakeholders in Charming Medical Ltd. The potential loss of its Nasdaq listing may diminish investor confidence and market visibility, impacting the company's ability to raise capital and attract new investors. Additionally, the delisting could lead to trading in the over-the-counter (OTC) market, where securities typically face lower liquidity and visibility.

What's Next

Charming Medical has until November 5, 2026, to file an appeal against the delisting determination. The company has indicated it will consult with legal advisors to determine its next steps. The outcome of this appeal will be crucial for the company’s future on the public markets.

For more details, the full press release can be accessed through the SEC filing at this link.